Dignitana AB Publishes Q3 Interim Report
Results and financial position Significant events during the period · Sales for the period amounted to 10,293 TSEK, $1,150 KUSD, an increase of 125 percent compared to the same period in 2017 and an increase of 14 percent compared to the second quarter 2018. · EBITDA amounted to (3,459) TSEK, ($386 KUSD), a 56 percent improvement compared to the same period in 2017. · 6 units were sold to facilities in countries outside the U.S. · Contracts for 7 locations in the U.S. were signed. · Third quarter treatment revenue in the U.S. increased over second quarter 2018. · In